Tirdzniecība CytomX Therapeutics Inc - CTMX CFD
Pievienot izlasei- Kopsavilkums
- Vēsturiskie Dati
- Notikumi
- Peļņas Atskaite
- Bilance
- Naudas Plūsma
- Īpašums
Tirdzniecības Nosacījumi
| Starpība | 0.05 | ||||||||
|
Garās pozīcijas nodeva naktij
Long position overnight fee
Doties uz platformu | -0.024068% | ||||||||
|
Īsās pozīcijas nodeva naktij
Short position overnight fee
Doties uz platformu | 0.001846% | ||||||||
| Nakts laika nodeva | 21:00 (UTC) | ||||||||
| Min. tirgotais daudzums | 1 | ||||||||
| Valūta | USD | ||||||||
| Drošības rezerve | 20% | ||||||||
| Fondu birža | United States of America | ||||||||
| Tirdzniecības komisija | 0% |
*Information provided by Capital.com
Galvenie Statistikas Dati
| Iepriekš. aizvērt* | 1.85 |
| Atvērt* | 1.78 |
| Izmaiņas par 1 gadu* | -3.78% |
| Dienas Diapazons* | 1.78 - 1.95 |
| 52 ned Diapazons | 1.17-3.12 |
| Vidējais apjoms (10 dienas) | 1.25M |
| Vidējais apjoms (3 mēneši) | 52.84M |
| Tirgus Kapitalizācija | 118.95M |
| Cenas/Peļņas Attiecība | -100.00K |
| Izvietotās Akcijas | 66.08M |
| Ieņēmumi | 71.94M |
| EPS | -1.49 |
| Dividende (Ienesīgums %) | N/A |
| Beta | 0.70 |
| Nākamās Peļņas Datums | Mar 23, 2023 |
"Visus datus nodrošina Refinitiv, izņemot datus, kas atzīmēti ar zvaigznīti, kas ir *dati, kurus nodrošina Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Aizvēršana | Change | Change (%) | Atvēršana | High | Low |
|---|---|---|---|---|---|---|
| Jun 29, 2022 | 1.86 | 0.04 | 2.20% | 1.82 | 1.96 | 1.78 |
| Jun 28, 2022 | 1.85 | -0.09 | -4.64% | 1.94 | 1.94 | 1.80 |
| Jun 27, 2022 | 1.92 | 0.04 | 2.13% | 1.88 | 1.97 | 1.83 |
| Jun 24, 2022 | 1.87 | -0.05 | -2.60% | 1.92 | 1.97 | 1.83 |
| Jun 23, 2022 | 1.84 | 0.14 | 8.24% | 1.70 | 1.85 | 1.70 |
| Jun 22, 2022 | 1.77 | 0.12 | 7.27% | 1.65 | 1.81 | 1.62 |
| Jun 21, 2022 | 1.68 | 0.06 | 3.70% | 1.62 | 1.71 | 1.58 |
| Jun 17, 2022 | 1.58 | -0.03 | -1.86% | 1.61 | 1.70 | 1.57 |
| Jun 16, 2022 | 1.63 | -0.04 | -2.40% | 1.67 | 1.67 | 1.57 |
| Jun 15, 2022 | 1.70 | 0.07 | 4.29% | 1.63 | 1.73 | 1.61 |
| Jun 14, 2022 | 1.65 | -0.05 | -2.94% | 1.70 | 1.72 | 1.64 |
| Jun 13, 2022 | 1.71 | -0.03 | -1.72% | 1.74 | 1.76 | 1.68 |
| Jun 10, 2022 | 1.83 | -0.02 | -1.08% | 1.85 | 1.85 | 1.77 |
| Jun 9, 2022 | 1.92 | 0.07 | 3.78% | 1.85 | 1.93 | 1.81 |
| Jun 8, 2022 | 1.88 | 0.02 | 1.08% | 1.86 | 1.98 | 1.86 |
| Jun 7, 2022 | 1.86 | 0.16 | 9.41% | 1.70 | 1.91 | 1.67 |
| Jun 6, 2022 | 1.71 | -0.06 | -3.39% | 1.77 | 1.83 | 1.71 |
| Jun 3, 2022 | 1.76 | 0.22 | 14.29% | 1.54 | 1.78 | 1.54 |
| Jun 2, 2022 | 1.58 | 0.06 | 3.95% | 1.52 | 1.59 | 1.49 |
| Jun 1, 2022 | 1.53 | -0.05 | -3.16% | 1.58 | 1.67 | 1.50 |
CytomX Therapeutics Inc Events
| Laiks (UTC) (UTC) | Valsts | Notikums |
|---|---|---|
| No events scheduled | ||
- Ikgadējs
- Ceturkšņa
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Kopējie ienākumi | 69.573 | 100.362 | 57.489 | 59.502 | 71.623 |
| Ienākumi | 69.573 | 100.362 | 57.489 | 59.502 | 71.623 |
| Kopējie Darbības Izdevumi | 153.354 | 148.967 | 168.384 | 137.376 | 117.882 |
| Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 39.16 | 36.031 | 36.765 | 33.51 | 25.605 |
| Pētniecība un Attīstība | 114.194 | 112.936 | 131.619 | 103.866 | 92.277 |
| Darbības Izdevumi | -83.781 | -48.605 | -110.895 | -77.874 | -46.259 |
| Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | 0.255 | 1.836 | 8.365 | 7.641 | 2.674 |
| Citi, Neto | -0.083 | -0.027 | -0.135 | -0.068 | -0.027 |
| Neto Ienākumi Pirms Nodokļu Nomaksas | -83.609 | -46.796 | -102.665 | -70.301 | -43.612 |
| Neto Ienākumi Pēc Nodokļu Nomaksas | -83.609 | -32.885 | -102.238 | -84.604 | -68.799 |
| Neto Ienākumi Pirms Ārkārtas Posteņiem | -83.609 | -32.885 | -102.238 | -84.604 | -68.799 |
| Neto Ienākumi | -83.609 | -32.885 | -102.238 | -84.604 | -43.099 |
| Total Adjustments to Net Income | 0 | ||||
| Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | -83.609 | -32.885 | -102.238 | -84.604 | -68.799 |
| Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | -83.609 | -32.885 | -102.238 | -84.604 | -43.099 |
| Atšķaidītie Neto Ienākumi | -83.609 | -32.885 | -102.238 | -84.604 | -43.099 |
| Atšķaidītie Ienākumi par Akcijām | 64.1469 | 46.1456 | 45.3359 | 41.6644 | 37.1668 |
| Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | -1.3034 | -0.71264 | -2.25512 | -2.03061 | -1.85109 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
| Atšķaidītā Normalizētā Peļņa par Akciju | -1.3034 | -0.71264 | -2.25512 | -2.03061 | -1.85109 |
| Ārkārtas Posteņi Kopā | 25.7 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Kopējie ienākumi | 17.136 | 19.727 | 17.587 | 16.288 | 15.971 |
| Ienākumi | 17.136 | 19.727 | 17.587 | 16.288 | 15.971 |
| Kopējie Darbības Izdevumi | 41.102 | 46.035 | 40.228 | 35.493 | 31.598 |
| Pārdošanas/Vispārīgi/Admin. Izdevumi, Kopā | 10.543 | 9.456 | 11.085 | 9.393 | 9.227 |
| Pētniecība un Attīstība | 30.559 | 36.579 | 29.143 | 26.1 | 22.371 |
| Darbības Izdevumi | -23.966 | -26.308 | -22.641 | -19.205 | -15.627 |
| Ienākumi no Procentiem (Izdevumi), Neto, ar Darbību Nesaistītie | 0.068 | 0.073 | 0.07 | 0.044 | 0.068 |
| Citi, Neto | 0.013 | 0.007 | -0.013 | -0.082 | 0.005 |
| Neto Ienākumi Pirms Nodokļu Nomaksas | -23.885 | -26.228 | -22.584 | -19.243 | -15.554 |
| Neto Ienākumi Pēc Nodokļu Nomaksas | -23.885 | -26.228 | -22.584 | -19.243 | -15.554 |
| Neto Ienākumi Pirms Ārkārtas Posteņiem | -23.885 | -26.228 | -22.584 | -19.243 | -15.554 |
| Neto Ienākumi | -23.885 | -26.228 | -22.584 | -19.243 | -15.554 |
| Kopējie Ienākumi, Izņemot Ārkārtas Posteņus | -23.885 | -26.228 | -22.584 | -19.243 | -15.554 |
| Kopējie Ienākumi, Ieskaitot Ārkārtas Posteņus | -23.885 | -26.228 | -22.584 | -19.243 | -15.554 |
| Atšķaidītie Neto Ienākumi | -23.885 | -26.228 | -22.584 | -19.243 | -15.554 |
| Atšķaidītie Ienākumi par Akcijām | 65.3937 | 65.3086 | 65.2081 | 65.056 | 60.9681 |
| Atšķaidītie Ienākumi, Izņemot Ārkārtas Posteņus | -0.36525 | -0.4016 | -0.34634 | -0.29579 | -0.25512 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Atšķaidītā Normalizētā Peļņa par Akciju | -0.36525 | -0.4016 | -0.34634 | -0.29579 | -0.25512 |
- Ikgadējs
- Ceturkšņa
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Apgrozāmo Līdzekļu Kopsumma | 310.301 | 324.013 | 303.335 | 445.475 | 388.601 |
| Nauda un Īstermiņa Ieguldījumi | 305.226 | 316.119 | 296.145 | 436.127 | 374.11 |
| Nauda un Ekvivalenti | 205.53 | 191.859 | 188.425 | 247.577 | 177.548 |
| Īstermiņa Ieguldījumi | 99.696 | 124.26 | 107.72 | 188.55 | 196.562 |
| Debitoru Parādu Kopsumma, Neto | 0.79 | 0.798 | 0.013 | 0.097 | 10.139 |
| Accounts Receivable - Trade, Net | 0.79 | 0.798 | 0.013 | 0.097 | 10.139 |
| Prepaid Expenses | 4.285 | 7.096 | 7.177 | 9.251 | 4.352 |
| Total Assets | 339.411 | 358.663 | 341.282 | 457.108 | 397.644 |
| Property/Plant/Equipment, Total - Net | 25.322 | 29.445 | 32.754 | 6.934 | 4.218 |
| Property/Plant/Equipment, Total - Gross | 39.154 | 40.871 | 41.804 | 13.88 | 9.426 |
| Accumulated Depreciation, Total | -13.832 | -11.426 | -9.05 | -6.946 | -5.208 |
| Goodwill, Net | 0.949 | 0.949 | 0.949 | 0.949 | 0.949 |
| Intangibles, Net | 1.021 | 1.167 | 1.312 | 1.458 | 1.604 |
| Other Long Term Assets, Total | 1.818 | 3.089 | 2.932 | 2.292 | 2.272 |
| Total Current Liabilities | 106.316 | 100.924 | 85.59 | 97.908 | 61.147 |
| Accounts Payable | 2.818 | 2.996 | 4.158 | 5.132 | 4.205 |
| Accrued Expenses | 34.236 | 23.059 | 30.051 | 26.724 | 16.383 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 69.262 | 74.869 | 51.381 | 66.052 | 40.559 |
| Total Liabilities | 250.032 | 308.86 | 290.169 | 326.225 | 327.748 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Income Tax | |||||
| Other Liabilities, Total | 143.716 | 207.936 | 204.579 | 228.317 | 266.601 |
| Total Equity | 89.379 | 49.803 | 51.113 | 130.883 | 69.896 |
| Common Stock | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 |
| Additional Paid-In Capital | 623.344 | 499.964 | 468.285 | 445.956 | 289.454 |
| Retained Earnings (Accumulated Deficit) | -533.724 | -450.115 | -417.23 | -314.981 | -219.465 |
| Other Equity, Total | -0.242 | -0.047 | 0.057 | -0.093 | -0.094 |
| Total Liabilities & Shareholders’ Equity | 339.411 | 358.663 | 341.282 | 457.108 | 397.644 |
| Total Common Shares Outstanding | 65.3928 | 48.2518 | 45.5231 | 45.0832 | 38.4786 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Apgrozāmo Līdzekļu Kopsumma | 268.444 | 310.301 | 240.998 | 271.005 | 400.008 |
| Nauda un Īstermiņa Ieguldījumi | 262.53 | 305.226 | 236.289 | 266.177 | 393.796 |
| Nauda un Ekvivalenti | 163.488 | 205.53 | 236.284 | 256.146 | 329.666 |
| Īstermiņa Ieguldījumi | 99.042 | 99.696 | 0.005 | 10.031 | 64.13 |
| Debitoru Parādu Kopsumma, Neto | 1.016 | 0.79 | 0.887 | 0.931 | 0.756 |
| Accounts Receivable - Trade, Net | 1.016 | 0.79 | 0.887 | 0.931 | 0.756 |
| Prepaid Expenses | 4.898 | 4.285 | 3.822 | 3.897 | 5.456 |
| Total Assets | 296.825 | 339.411 | 371.233 | 402.44 | 434.158 |
| Property/Plant/Equipment, Total - Net | 24.629 | 25.322 | 26.441 | 27.66 | 28.908 |
| Goodwill, Net | 0.949 | 0.949 | 0.949 | 0.949 | 0.949 |
| Intangibles, Net | 0.984 | 1.021 | 1.057 | 1.094 | 1.13 |
| Other Long Term Assets, Total | 1.819 | 1.818 | 1.819 | 1.818 | 3.163 |
| Total Current Liabilities | 102.766 | 106.316 | 99.772 | 93.377 | 98.049 |
| Accounts Payable | 1.721 | 2.818 | 1.516 | 1.755 | 2.582 |
| Accrued Expenses | 31.032 | 34.236 | 25.167 | 19.253 | 18.831 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 70.013 | 69.262 | 73.089 | 72.369 | 76.636 |
| Total Liabilities | 228.631 | 250.032 | 259.559 | 271.487 | 288.136 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 125.865 | 143.716 | 159.787 | 178.11 | 190.087 |
| Total Equity | 68.194 | 89.379 | 111.674 | 130.953 | 146.022 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | |||
| Common Stock | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 |
| Additional Paid-In Capital | 626.721 | 623.344 | 619.117 | 615.849 | 611.733 |
| Retained Earnings (Accumulated Deficit) | -557.609 | -533.724 | -507.496 | -484.912 | -465.669 |
| Other Equity, Total | -0.919 | -0.242 | 0.052 | 0.015 | -0.043 |
| Total Liabilities & Shareholders’ Equity | 296.825 | 339.411 | 371.233 | 402.44 | 434.158 |
| Total Common Shares Outstanding | 65.3984 | 65.3928 | 65.2491 | 65.157 | 65.0029 |
| Long Term Investments | 99.969 | 99.914 |
- Ikgadējs
- Ceturkšņa
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Neto ienākumi/Sākuma Līnija | -83.609 | -32.885 | -102.238 | -84.604 | -43.099 |
| Nauda no Darbības | -119.031 | 5.259 | -140.48 | -75.521 | 170.373 |
| Nauda no Darbības | 2.56 | 2.427 | 2.459 | 1.884 | 1.645 |
| Deferred Taxes | -0.513 | ||||
| Bezskaidras Naudas Preces | 16.572 | 17.437 | 18.474 | 15.177 | 22.375 |
| Izmaiņas Apgrozāmajā Kapitālā | -54.7 | 18.134 | -59.321 | -7.978 | 189.965 |
| Nauda no Ieguldījumu Darbībām | 22.489 | -18.718 | 79.701 | 5.926 | -121.266 |
| Kapitālie Izdevumi | -1.609 | -2.309 | -3.497 | -3.788 | -1.559 |
| Citi Ieguldījumu Naudas Plūsmas Posteņi, Kopā | 24.098 | -16.409 | 83.198 | 9.714 | -119.707 |
| Nauda no Darbībām ar Finansēšanu | 110.213 | 16.893 | 1.627 | 139.624 | 23.796 |
| Naudas Plūsma Finansēšanas Posteņos | 0 | 0 | |||
| Akciju Izsniegšana (Atkāpšanās), Neto | 110.213 | 16.893 | 1.627 | 139.624 | 23.796 |
| Parādu Izsniegšana (Atkāpšanās), Neto | 0 | ||||
| Neto Izmaiņas Naudā | 13.671 | 3.434 | -59.152 | 70.029 | 72.903 |
| Amortization | 0.146 | 0.146 | 0.146 | ||
| Cash Taxes Paid | 0 | 0 | 13.061 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -23.885 | -83.609 | -57.381 | -34.797 | -15.554 |
| Cash From Operating Activities | -41.313 | -119.031 | -87.839 | -58.139 | -29.94 |
| Cash From Operating Activities | 0.565 | 2.56 | 1.921 | 1.278 | 0.638 |
| Amortization | 0.037 | 0.146 | 0.11 | 0.073 | 0.036 |
| Non-Cash Items | 4.179 | 16.572 | 12.235 | 8.274 | 3.934 |
| Changes in Working Capital | -22.209 | -54.7 | -44.724 | -32.967 | -18.994 |
| Cash From Investing Activities | -0.736 | 22.489 | 22.734 | 13 | 59.012 |
| Capital Expenditures | -0.736 | -1.609 | -1.364 | -1.096 | -0.982 |
| Other Investing Cash Flow Items, Total | 0 | 24.098 | 24.098 | 14.096 | 59.994 |
| Cash From Financing Activities | 0.007 | 110.213 | 109.53 | 109.426 | 108.735 |
| Issuance (Retirement) of Stock, Net | 0.007 | 110.213 | 109.53 | 109.426 | 108.735 |
| Net Change in Cash | -42.042 | 13.671 | 44.425 | 64.287 | 137.807 |
| Investora vārds | Investora veids | Nenokārtots procents | Akcijas turējumā | Izmaiņas akcijās | Turēšanas termiņš | Apgrozījuma reitings |
|---|---|---|---|---|---|---|
| BVF Partners L.P. | Hedge Fund | 9.9809 | 6595801 | 0 | 2022-12-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 6.9392 | 4585721 | 47760 | 2022-12-31 | LOW |
| Tang Capital Management, LLC | Hedge Fund | 5.3121 | 3510445 | 10445 | 2022-12-31 | MED |
| Acadian Asset Management LLC | Investment Advisor/Hedge Fund | 4.0154 | 2653576 | 0 | 2022-12-31 | MED |
| Rubric Capital Management LP | Hedge Fund | 3.6415 | 2406449 | 0 | 2022-12-31 | MED |
| Millennium Management LLC | Hedge Fund | 2.6024 | 1719811 | 1187298 | 2022-12-31 | HIGH |
| Medical Strategy GmbH | Investment Advisor | 2.5583 | 1690646 | 0 | 2022-09-30 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 2.0289 | 1340774 | -464826 | 2022-12-31 | HIGH |
| Two Sigma Investments, LP | Hedge Fund | 1.9581 | 1293989 | 408628 | 2022-12-31 | HIGH |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.9432 | 1284168 | -468950 | 2022-12-31 | LOW |
| Laurion Capital Management LP | Hedge Fund | 1.9231 | 1270900 | 0 | 2022-12-31 | HIGH |
| Assenagon Asset Management S.A. | Investment Advisor | 1.3844 | 914900 | -150492 | 2022-12-31 | HIGH |
| Fidelity Management & Research Company LLC | Investment Advisor | 1.0582 | 699283 | 15074 | 2022-12-31 | LOW |
| Jacobs Levy Equity Management, Inc. | Investment Advisor/Hedge Fund | 1.045 | 690609 | -438449 | 2022-12-31 | MED |
| Platinum Asset Management | Investment Advisor/Hedge Fund | 0.9621 | 635798 | -593747 | 2022-12-31 | LOW |
| D. E. Shaw & Co., L.P. | Hedge Fund | 0.9357 | 618374 | 128744 | 2022-12-31 | MED |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.9126 | 603075 | 15624 | 2022-12-31 | LOW |
| Newtyn Management, LLC | Hedge Fund | 0.8625 | 570000 | -230000 | 2022-12-31 | MED |
| Oasis Management Company Ltd. | Investment Advisor/Hedge Fund | 0.818 | 540541 | 0 | 2022-12-31 | LOW |
| Gluck (Frederick W) | Individual Investor | 0.8021 | 530069 | 0 | 2022-04-18 | LOW |
Kāpēc izvēlēties Capital.com? Mūsu skaitļi runā paši par sevi.
Capital.com Group500K+
Tirgotāji
92K+
Ikmēneša aktīvie klienti
$53M+
Ikmēneša ieguldījumu apjoms
$30M+
Izņemts katru mēnesi
Treidinga kalkulators
Aprēķiniet iespējamo peļņu un zaudējumus, uzsākot CFD darījumu noteiktā dienā (izvēlaties datumu) un slēdzot darījumu citā dienā (izvēlaties datumu).
Tirdzniecības komisija
0
- 1:1
Finanšu svira
1:1
- 20
- 100
- 500
- 1000
- 10000
Investīcija
Darījuma apjoms (Kredītplecs x Investīcija):
Atvēršana
Aizvēršana
Īss Garšs
CytomX Therapeutics Inc Company profile
Par CytomX Therapeutics Inc
CytomX Therapeutics, Inc. ir klīniskās stadijas, uz onkoloģiju orientēts biofarmācijas uzņēmums. Uzņēmums izstrādā pētāmo nosacīti aktivizēto terapeitisko līdzekļu grupu, kas balstīta uz Probody tehnoloģisko platformu, vēža ārstēšanai. Uzņēmuma Probody tehnoloģiskā platforma ir izstrādāta tā, lai nodrošinātu uz antivielām balstītu zāļu nosacītu aktivizāciju audzēja mikrovidē, vienlaikus samazinot zāļu aktivitāti veselos audos un apritē. Uzņēmuma kandidātprodukti ietver nosacīti aktivizētus antivielu un zāļu konjugātus (ADC) praluzatamaba ravtansīnu (CX2009, kas vērsts pret CD166) un CX-2029, kas vērsts pret CD71, un Probody imūno kontrolpunktu inhibitorus pakmilimabu (CX-072, kas vērsts pret PD-L1) un BMS-986249 (vērsts pret CTLA-4). Uzņēmumam ir arī divi preklīniski preparāti, kas atrodas jaunu zāļu izpēti (IND) veicinošos pētījumos - nosacīti aktivēta ADC, kas vērsta pret EpCAM/Trop-1 (CX-2043), un nosacīti aktivēta T šūnas iesaistoša bispecifiska antiviela, kas vērsta pret EGFR un CD3 (CX-904).
| Industry: | Bio Therapeutic Drugs |
650 Gateway Blvd.
Suite 125
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US
Peļņas Atskaite
- Annual
- Quarterly
Cilvēki arī skatās
Vai joprojām meklējat mākleri, kuram varat uzticēties?
Pievienojieties 500 000+ tirgotājiem visā pasaulē, kuri izvēlējās tirgoties ar Capital.com